|
- Bioequivalence - Wikipedia
Bioequivalence is a term in pharmacokinetics used to assess the expected in vivo biological equivalence of two proprietary preparations of a drug If two products are said to be bioequivalent it means that they would be expected to be, for all intents and purposes, the same
- Bioequivalence | FDA
Two products are considered to be bioequivalent when they are equal in the rate and extent to which the active pharmaceutical ingredient (API) becomes available at the site (s) of drug action
- Bioequivalence: Definition, Testing, FDA Approval Standards
Bioequivalence requires that two drugs release the active ingredient into the bloodstream in the same dose, at the same absorption rate, and with the same quality The FDA's bioequivalence
- Bioequivalence; Its History, Practice, and Future - PMC
The concepts of bioavailability (BA) and bioequivalence have gained considerable importance during the last three decades because of their application to new brand-name drugs, as well as to generic drugs
- Bioequivalence in Pharmacokinetics Explained
Bioequivalence is a critical concept in pharmacokinetics that plays a crucial role in the development and approval of generic drugs The demonstration of bioequivalence ensures that generic drugs are as safe and effective as their brand-name counterparts
- Bioequivalence | SpringerLink
BE studies are developed to compare the biopharmaceutics quality of two pharmaceutical products that have different origins (pharmaceutical equivalents or pharmaceutical alternatives), one of them being the reference product (comparator) defined by each Medicine Regulatory Agency (MRA)
- BIOEQUIVALENCE Definition Meaning - Merriam-Webster
The meaning of BIOEQUIVALENCE is the property wherein two drugs with identical active ingredients or two different dosage forms of the same drug possess similar bioavailability and produce the same effect at the site of physiological activity
- Investigation of bioequivalence - Scientific guideline | European . . .
This guidance specifies the requirements for the design, conduct, and evaluation of bioequivalence studies for immediate release dosage forms with systemic action
|
|
|